Generic Austedo Availability
Last updated on Apr 10, 2025.
See also: Generic Austedo XR
Austedo is a brand name of deutetrabenazine, approved by the FDA in the following formulation(s):
AUSTEDO (deutetrabenazine - tablet;oral)
-
Manufacturer: TEVA BRANDED PHARM
Approval date: April 3, 2017
Strength(s): 6MG [RLD], 9MG [RLD], 12MG [RLD]
Is there a generic version of Austedo available?
No. There is currently no therapeutically equivalent version of Austedo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Austedo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 10,959,996
Issued: March 30, 2021
Inventor(s): Stamler David & Huang Michael Fangching
Assignee(s): AUSPEX PHARMACEUTICALS, INC.Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- March 7, 2036✓
- March 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 10959996*PE
Issued: March 30, 2021
Inventor(s): Stamler David & Huang Michael Fangching
Assignee(s): AUSPEX PHARMACEUTICALS, INC.Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- September 7, 2036
- September 7, 2036
-
Analogs of deutetrabenazine, their preparation and use
Patent 11,179,386
Issued: November 23, 2021
Inventor(s): Zhang Chengzhi & Kerr James
Assignee(s): AUSPEX PHARMACEUTICALS, INC.The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Patent expiration dates:
- March 15, 2038✓✓
- March 15, 2038✓✓
- March 15, 2038
-
Analogs of deutetrabenazine, their preparation and use
Patent 11179386*PE
Issued: November 23, 2021
Inventor(s): Zhang Chengzhi & Kerr James
Assignee(s): AUSPEX PHARMACEUTICALS, INC.The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Patent expiration dates:
- September 15, 2038
- September 15, 2038
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11,357,772
Issued: June 14, 2022
Inventor(s): Stamler David & Huang Michael
Assignee(s): AUSPEX PHARMACEUTICALS, INC.Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- March 7, 2036✓
- March 7, 2036✓
- March 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11357772*PE
Issued: June 14, 2022
Inventor(s): Stamler David & Huang Michael
Assignee(s): AUSPEX PHARMACEUTICALS, INC.Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- September 7, 2036
- September 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11,446,291
Issued: September 20, 2022
Inventor(s): Stamler David & Huang Michael Fangching
Assignee(s): Auspex Pharmaceuticals, Inc.Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- March 7, 2036✓
- March 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11446291*PE
Issued: September 20, 2022
Inventor(s): Stamler David & Huang Michael Fangching
Assignee(s): Auspex Pharmaceuticals, Inc.Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- September 7, 2036
- September 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11,564,917
Issued: January 31, 2023
Inventor(s): Stamler; David et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- March 7, 2036✓
- March 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11564917*PE
Issued: January 31, 2023
Inventor(s): Stamler; David et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- September 7, 2036
- September 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11,648,244
Issued: May 16, 2023
Inventor(s): Stamler; David et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- March 7, 2036✓
- March 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 11648244*PE
Issued: May 16, 2023
Inventor(s): Stamler; David et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- September 7, 2036
- September 7, 2036
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 11,666,566
Issued: June 6, 2023
Inventor(s): Sommer; Andreas et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- September 18, 2033✓
- September 18, 2033
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 11666566*PE
Issued: June 6, 2023
Inventor(s): Sommer; Andreas et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- March 18, 2034
- March 18, 2034
-
Analogs of deutetrabenazine, their preparation and use
Patent 11,813,232
Issued: November 14, 2023
Inventor(s): Zhang; Chengzhi et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Patent expiration dates:
- March 15, 2038✓
- March 15, 2038
-
Analogs of deutetrabenazine, their preparation and use
Patent 11813232*PE
Issued: November 14, 2023
Inventor(s): Zhang; Chengzhi et al.
Assignee(s): Auspex Pharmaceuticals, Inc. (Parsippany, NJ)The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Patent expiration dates:
- September 15, 2038
- September 15, 2038
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 12,016,858
Issued: June 25, 2024
Inventor(s): Stamler; David et al.
Assignee(s): AUSPEX PHARMACEUTICALS, INC. (Parsippany, NJ)Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- March 7, 2036✓
- March 7, 2036✓
- March 7, 2036
-
Methods for the treatment of abnormal involuntary movement disorders
Patent 12016858*PE
Issued: June 25, 2024
Inventor(s): Stamler; David et al.
Assignee(s): AUSPEX PHARMACEUTICALS, INC. (Parsippany, NJ)Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Patent expiration dates:
- September 7, 2036
- September 7, 2036
-
Benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 8,524,733
Issued: September 3, 2013
Inventor(s): Gant Thomas G. & Shahbaz Manoucherhr M.
Assignee(s): Auspex PharmaceuticalsThe present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
Patent expiration dates:
- April 3, 2031✓✓
- April 3, 2031
-
Benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 8524733*PED
Issued: September 3, 2013
Inventor(s): Gant Thomas G. & Shahbaz Manoucherhr M.
Assignee(s): Auspex PharmaceuticalsThe present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
Patent expiration dates:
- October 3, 2031✓
- October 3, 2031
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9,233,959
Issued: January 12, 2016
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- September 18, 2033✓
- September 18, 2033
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9233959*PED
Issued: January 12, 2016
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- March 18, 2034✓
- March 18, 2034
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9,296,739
Issued: March 29, 2016
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- September 18, 2033✓
- September 18, 2033
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9296739*PED
Issued: March 29, 2016
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- March 18, 2034✓
- March 18, 2034
-
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9,550,780
Issued: January 24, 2017
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- September 18, 2033✓✓✓
- September 18, 2033✓✓✓
- September 18, 2033
-
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9550780*PED
Issued: January 24, 2017
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- March 18, 2034✓
- March 18, 2034
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9,814,708
Issued: November 14, 2017
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- September 18, 2033✓
- September 18, 2033
-
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent 9814708*PED
Issued: November 14, 2017
Inventor(s): Sommer Andreas & Zhang Chengzhi & Carter John & Arthur John & Bradbury Margaret & Gant Thomas & Shahbaz Manouchehr
Assignee(s): Auspex Pharmaceuticals, Inc.The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Patent expiration dates:
- March 18, 2034✓
- March 18, 2034
More about Austedo (deutetrabenazine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (12)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: VMAT2 inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.